Key facts
- KOKO Medical’s last known valuation is $48.0M (Feb 2026).
- It has raised $30.4M across 2 recorded rounds; the latest was Early Stage VC ($8.0M) in Feb 2026.
- Notable investors include ShangBay Capital, Amzak Health.
- KOKO Medical has filed 2 Form Ds with the SEC since 2023, most recently Feb 2026 ($8.0M sold to 29 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for KOKO Medical
Funding rounds
2 roundsAbout KOKO Medical
Developer of a medical device designed to offer rapid postpartum hemorrhage intervention. The company utilizes catheter-based technology that contains a fabric that grasps cells as they navigate through the fallopian tubes during a hysteroscopic procedure and collects cells that can be tested for early cancer indicators, enabling healthcare providers to detect the early stages of ovarian cancer, provide initial treatment, and reduce unnecessary fertility-ending surgeries.
- Sector
- Healthcare
- HQ
- Exton, PA, United States
- Founded
- 2020
- Employees
- 6
- Website
- kokomed.com/
- Ownership
- Privately Held (backing)
KOKO Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KOKO Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KOKO Medical in its N-PORT filings yet. We sweep new filings monthly.